Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

AI-Assisted 3D Reconstruction for Lung Resection Planning

This prospective observational study aims to validate an artificial intelligence (AI)-based system for automated three-dimensional (3D) reconstruction of pulmonary anatomy from preoperative chest computed tomography (CT) scans in patients undergoing lung resection. The AI system will automatically identify and reconstruct relevant pulmonary anatomical structures, including pulmonary arteries, veins, bronchi, lobes, and segments. AI-generated 3D reconstructions will be compared with expert manual 3D reconstructions and with anatomical findings documented during surgery. The primary objective is to assess the anatomical accuracy of AI-generated 3D reconstructions in identifying surgically relevant bronchovascular anatomy and anatomical variants. Secondary objectives include evaluating accuracy for individual anatomical structures, discrepancies between automated and manual reconstructions, concordance with intraoperative findings, and the time required to generate and review the automated reconstruction. The study is observational and will not modify the planned surgical procedure or standard patient care.

Participants needed: 50
Trial details
Age: 18+Biological sex: AllType: ObservationalSponsor: S. Andrea HospitalUpdated: Oct 1, 2026Locations: 1
Eligibility criteria

Age ≥18 years [+3]

Preoperative CT images of insufficient quality or technical characteristics for... [+2]

Status: Recruiting

Bacille Calmette-Guérin (BCG) Vaccine In Radiologically Isolated Syndrome (RIS)

Multiple sclerosis (MS) witnessed relevant therapeutic progress in the last decade. Following the extraordinary progress in the treatment of relapsing-remitting (RR) multiple sclerosis (MS), two major unmet needs remain to be addressed by translational research in this field: progressive MS and the "dream" of a world free of MS. As far as the latter is concerned, the investigators can hope to make the dream come true by understanding the etiology of the disease and hence design definitive cures. A more realistic and pragmatic perspective may be the prevention of the clinical onset of the disease, a research field that promises to become increasingly important as the integration of genetic data with endophenotypes, magnetic resonance imaging and other biomarkers ameliorates the ability to predict the development of the disease under clinical circumstance. Bacille Calmette-Guerin (BCG) vaccine has been tested with encouraging results in early MS and clinically isolated syndrome (CIS). The knowledge that disease-modifying therapies work best when used early in the demyelinating process raises the question about whether to try this approach - which is safe, cheap and handy - in individuals with radiologically isolated syndrome (RIS). Radiologically isolated syndrome is a new entity, diagnosed when the unanticipated magnetic resonance imaging (MRI) finding of brain spatial dissemination of focal white matter (WM) lesions highly suggestive of MS occurs in subjects without symptoms of MS, and with normal neurological examinations. Conversion to clinically isolated syndromes (CIS) were described in 84% of RIS individuals with spinal cord lesions over a median time of 1.6 years from the date of the first MRI. Whether or not to treat this condition remains currently a clinical conundrum. Bacille Calmette-Guérin (BCG) vaccine may have these characteristics since it resulted beneficial in early MS and first demyelinating episodes. Being safe, cheap and handy, the investigators propose to investigate its use to prevent progression of the demyelinating process in radiologically isolated syndrome. An approach such as BCG vaccine seems appropriate as a front-line immunomodulatory approach for RIS people. In a pilot study BCG vaccine was safe and effective in reducing disease activity at MRI, and the risk of developing persistent T1-hypointense lesions ('black holes' -BH- expression of tissue damage) in subjects with MS.

Participants needed: 100
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: S. Andrea HospitalUpdated: Nov 29, 2024Locations: 1
Eligibility criteria

Male and female of any race and > 18 years old. [+2]

Pregnancy or lactation. [+8]

Status: Recruiting

Riluzole in Patients With Spinocerebellar Ataxia Type 7

Spinocerebellar ataxia type 7 (SCA7) belongs to the dominant forms of inherited cerebellar ataxias (CA), being one of the rarest form. SCA7 has no therapeutic options, so that the relentless course, the important visual deficit that accompanies CA, and the possibility of disease development in childhood are pressing unmet needs. The investigators published encouraging data on riluzole in inherited CA other than SCA7. These results prompted off-label use of riluzole in single cases of SCA7 in Italy and United States, suggesting possible efficacy of the drug in this condition.

Participants needed: 34
Trial details
Phase: Phase 2, Phase 3Age: 7+Biological sex: AllType: InterventionalSponsor: S. Andrea HospitalUpdated: Dec 2, 2024Locations: 1
Eligibility criteria

positive genetic test for SCA7.

cardiac arrhythmias; [+4]